Is MINT the next BRIC?
In 2001, British economist Jim O’Neill coined the now ubiquitous acronym ‘BRIC’, to stand for the four emerging economies of Brazil, Russia, India and China, which he suggested were all poised for massive economic growth. Earlier this year, O’Neill came out of retirement to generate buzz about ‘MINT’ – that’s Mexico, Indonesia, Nigeria and Turkey to the uninitiated – as the next generation ‘ones to watch’ in the coming twenty years.
So what does this mean to the healthcare market and to us as market researchers? With almost 40% of studies conducted by Research Partnership last year having included at least one emerging market, we are well aware that growing economies often translate to growing spend on healthcare and pharmaceuticals – and therefore increasing interest from our clients. And we in the Emerging Markets team recognise that emerging markets are much more than BRIC, having conducted research in 28 other emerging markets in the last year (including Mexico, Turkey and Indonesia).
While we were initially surprised at Nigeria’s inclusion, according to the 2012 UN World Population Prospects report, its population is predicted to surpass that of the US by 2050. As we have seen in markets like India, the sheer number of people can mean countries can be important players even when only a tiny fraction of the population can afford premium-priced pharmaceuticals.
In the context of healthcare, however, applying a broad-brush approach and assuming that economic growth automatically results in huge opportunity for the pharmaceutical industry may overlook important demographic, socio-political and healthcare system differences that may influence market potential. For example, the population of Indonesia is overwhelmingly young, so it has a very different disease profile from some of the other emerging markets in the region, such as China. If we look back at the trends we have seen in the BRIC markets since they were so-named, the pharmaceutical industry has faced different challenges in each of them. For example: governmental promotion of generics in Brazil, heavy pharmaceutical marketing restrictions in Russia, controversial patent legislation in India and the recent clampdown on industry corruption in China.
Among the MINT markets, the political conflict in Nigeria’s Northern States remains fragile, the Mexican drug war is an ongoing drain on the economy, while both Turkey and Indonesia have struggled with conflict arising from Islamic extremism in recent years). We in the Emerging Markets team have recently seen stronger interest in the traditionally less-feted markets of Vietnam, Colombia and Saudi Arabia.
Therefore while MINT undoubtedly provides an interesting indication of where future work may come from and where we can consider developing our capabilities, we by no means see it as an exclusive or definitive list of emerging markets that will prove important for healthcare market research in the coming decades.
We will continue to monitor the MINT market, and aim to examine each of the markets in more detail in future blogs – watch this space!
Research Partnership is one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.
Research Partnership is one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. Find out more here: http://bit.ly/1F7qLGR
This content was provided by Research Partnership
Company Details
Latest Content from Research Partnership
Research Partnership appoints new CEO
Research Partnership has appointed Gareth Phillips to take over as CEO
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study.
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space.
How to elevate your communications testing with AI powered insights and analytics
Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers
Infographic: Therapy Watch Psoriasis
Our PsO infographic offers an introduction to the real-world patient insights collected by our Therapy Watch PsO study.
Article: How behavioural economics can help you build better brand communications
For pharma marketers, accelerating brand performance means maximizing return on investment. Your campaigns need to trigger the right emotions, and the right actions, in your audience.
Article: From KOLs to KOIs – How to identify and engage the new healthcare influencers
Paul Reed and Basil Feilding investigate a new breed of KOLs with online influence and explain why pharma needs to join the conversation.
New syndicated patient reports –
Living with Uterine Fibroids and Endometriosis US 2022
Webcast: From perceptions to prescribing: Combining forces with next-generation tracking and benchmarking to accelerate brand performance
In this webcast we demonstrate RP and STEM's integrated approaches which gives clients the level of insights they need to accelerate brand performance.
Animation: Living With
The journey from the patient's perspective